Stay updated with breaking news from Desbois mackenzie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs Ipsen will now lead all development ....
Identification of ten novel tumor-specific antigens immunogenic for T cells Planegg/Martinsried and Montréal - 10 April 2021. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today presents the screening and identification of novel immunogenic tumor-specific antigens (TSAs) derived from non-coding regions of the human genome at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2021. The poster can be found on Medigene s website: https://www.medigene.com/technologies/abstracts Significant efforts are being dedicated worldwide to identifying novel TSAs as targets for cancer immunotherapy. In this respect, not only known proteins but also non-coding genetic regions of cells are studied as sources of peptides that can be presented by HLA molecules at the surface of tumor cells and be recognized by T cell receptors (TCRs). Such TSAs can provide new targets ....
, 2020 Today, IRICoR and Ovarian Cancer Canada are proud to announce the three winners of this competition, which aims to support research efforts related to the discovery of new treatments for women with ovarian cancer. A total $2.3M will be invested over the next two (2) years, namely $1.15M from IRICoR and $1.15M from Ovarian Cancer Canada s OvCAN initiative, largely funded by Health Canada. The LeadAction Ovarian Cancer Competition is a powerful example of collaboration at its best. Together with IRICoR, a leader in the field of drug discovery, we invited two women with lived experience of ovarian cancer to the decision table to contribute firsthand insights, says Elisabeth Baugh, Chief Executive Officer, Ovarian Cancer Canada. Given the high caliber of these projects, we look forward to seeing results that help women with ovarian cancer live fuller, better and longer lives. ....